2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 208-210
Technology and Procedures, Molecular Testing, Treatment Considerations, Artificial Intelligence (AI), Natural Language Processing, Biological Processes, Genomics, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Lymphoid Malignancies, Plasma Cell Disorders, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

34 Venous thromboembolism, thrombotic microangiopathy and hemorrhagic events in transplant-eligible newly diagnosed multiple myeloma treated with isatuximab-carfilzomib-lenalidomide-dexamethasone: Data from 791 patients enrolled in the IFM MIDAS phase 3 trial

Laurent Frenzel, MD, PhD, Jerome Lambert, PhD2, Cyrille Touzeau Sr, MD, PhD3, Cyrille Hulin, MD4, Andrea Pieragostini, MD5, Lionel Karlin, MD6, Bertrand Arnulf Sr, MD, PhD7, Philippe Rey, MD8, Laurent Garderet9, Magaret Macro, MD10, Martine Escoffre-Barbe11, Julie Gay, MD12, Thomas Chalopin Jr, MD13, Laure Vincent Jr, MD14, Jean Marc Schiano De Colella, MD15, Mohamad Mohty, MD, PhD16, Salomon Manier, MD, PhD17, Xavier Leleu Sr, MD, PhD18, Romain Gounot19, Komivi Gedeon Agbetsivi, MD20, Emilie Chalayer, MD, PhD21, Nathalie Meuleman, MD, PhD22, Noemie Bigot I23, Philippe Moreau Sr, MD, PhD24, Aurore Perrot Sr, MD25
1 MSKCC, New York, New York, United States, Necker Hospital, Paris, IDF, France
2 Université Paris Cité, Inserm, Institut de Recherche Saint Louis (IRSL), Service de Biostatistique et Information Médicale, AP-HP, Hôpital Saint Louis, Paris, France
3 CHRU Hôtel Dieu, Nantes, France
4 CHU Bordeaux - Hôpital Haut Lévêque - Centre F. Magendi Pessac,, Bordeaux, France
5 CHU Dijon,, Dijon, France
6 Centre Hospitalier Lyon Sud, Lyon, France
7 Hôpital Saint=Louis, Paris, France
8 Centre Léon Bérard, Lyon, France
9 Hôpital Universitaire Pitié-Salpêtrière, Paris, France
10 CHU Caen-Côte de Nacre, Caen, France
11 CHRU Hôpital de Pontchaillou, Rennes, France
12 Centre hospitalier de la Côte Basque, Bayonne, France
13 CHRU Hôpital Bretonneau - Centre Henry Kaplan, Tours, France
14 Hopital Saint Eloi - CHU, Montpellier, France
15 Institut Paoli-Calmettes, Marseille, France
16 Hôpital Saint-Antoine, Paris, France
17 Centre Hospitalier Universitaire, Lille, France
18 CHU Poitiers - Pôle régional de Cancérologie, Poitiers, France
19 Hôpital Mondor, Paris, France
20 CH Départemental Vendée, La Roche sur Yon, France
21 Centre Hospitalier Universitaire (CHU), Saint-Etienne, France
22 Institut Jules Bordet, Hôpitaux Universitaires de Bruxelles (H.U.B), Université Libre de Bruxelles (ULB), Bruxelles, Belgium
23 Université Paris Cité, Inserm, Institut de Recherche Saint Louis (IRSL), Service de Biostatistique et Information Médicale, AP-HP, Hôpital Saint Louis, Paris, France
24 CHRU Hôtel Dieu, Nantes, France
25 Pôle IUCT Oncopole CHU, Toulouse, France
Introduction: Venous thromboembolism (VTE) is a frequent and early complication of transplant-eligible newly diagnosed multiple myeloma (TE-NDMM), occurring in 5% to 15% of patients within the first months. Carfilzomib combined with an immunomodulatory drug (IMiD) and dexamethasone may further increase this risk and is the main cause of thrombotic microangiopathy (TMA) in myeloma, a complication rarely seen with other agents. Despite growing evidence supporting DOAC for thromboprophylaxis in myeloma, an off-label use, no large clinical trial has described thrombotic and hemorrhagic events, or antithrombotic management, in TE-NDMM receiving a carfilzomib-based quadruplet.

Aim: To describe the incidence, type, timing, severity and management of venous thromboembolic, hemorrhagic and TMA events in TE-NDMM treated with Isa-KRD induction and MRD-adapted consolidation with or without ASCT.

Methods: In IFM MIDAS (NCT04934475), 791 TE-NDMM patients <66 years received 6 cycles of Isa-KRD induction, followed by MRD-adapted randomization: MRD-negative patients to Isa-KRD consolidation without (arm A) or with autologous stem cell transplantation (ASCT; arm B), and MRD-positive patients to single (arm C) or tandem (arm D) ASCT plus Isa-KRD. Venous thromboembolic, hemorrhagic and TMA events during induction and consolidation were collected as adverse events and graded per CTCAE. All antithrombotic treatments (ATT) were recorded per patient with start and stop dates.

Results: Overall, 87/791 patients (11%) experienced at least one event (94 in total): 51 (6%) VTE, 29 (4%) hemorrhage and 10 (1%) TMA, some patients having more than one event type. VTE events included deep vein thrombosis (39; 5%, mostly grade 2), pulmonary embolism (11; 1%, including 10 grade ≥3 events), and one catheter-related thrombosis. Hemorrhages were mostly grade 1-2 (3 grade 3, no grade 4). TMA were severe (8/10 grade 3-4). VTE and hemorrhage occurred early, mostly during induction (median 3.8 and 3.1 months from Isa-KRD initiation), whereas TMA occurred later, exclusively during consolidation (median 9.3 months, range 8.6-11.4), across arms but concentrated in arm B (arm A, n=2; arm B, n=6; arm C, n=2; tandem arm D, n=0), consistent with carfilzomib re-exposure rather than transplantation. During consolidation, more patients had an event in arm B than arm A (16/242 [7%] vs 10/243 [4%]), mainly TMA and thrombosis. Seven deaths occurred during induction and consolidation, none attributed to VTE or hemorrhage.
At least one ATT was given to 757 patients (96%): 653 (83%) were treated with an anticoagulant (DOAC in 563 [71%], mostly apixaban [66%] and rivaroxaban [5%]; LMWH in 293 [37%]) and 347 (44%) with aspirin; 34 (4%) received none. ATT was initiated early (median 0 days from Isa-KRD start), 200 patients being already treated before induction, and 475 (63%) received ≥2 agents, concomitantly or sequentially. Prophylaxis was frequently switched from aspirin or heparin to a DOAC during the first months and interrupted around ASCT, with substantial variation in the choice of agent across the 72 participating centers. No baseline characteristic (age, ISS, cytogenetics) was associated with VTE. Before the event, patients who developed VTE more often had received no antithrombotic prophylaxis than those without VTE (8/51 [16%] vs 34/740 [5%]; P=0.004), and 16/51 (31%) were on aspirin alone. Overall, about half of VTE occurred in patients who had received no anticoagulant prophylaxis (none or aspirin alone), the other half in patients who had received an anticoagulant (DOAC or LMWH).After a VTE, 49/51 patients (96%) started or escalated therapeutic anticoagulation. Most bleeding events were low-grade, and after a bleed, most patients (20/29, 69%) did not start a new antithrombotic treatment.

Conclusion: In these 791 TE-NDMM patients uniformly treated with a carfilzomib-based quadruplet, thrombotic and hemorrhagic events were uncommon, rarely severe and never fatal. The VTE rate (6%) was lower than expected with carfilzomib-IMiD regimens, likely reflecting near-universal DOAC prophylaxis, and was associated only with the absence of anticoagulation or aspirin alone, supporting preferential use of DOAC over aspirin for thromboprophylaxis whenever appropriate. TMA was a distinct, later and more severe complication occurring despite effective anticoagulation, warranting dedicated investigation.
Laurent Frenzel, MD, PhD: Roche - Honoraria; Sobi - Honoraria; Johnson & johnson - Honoraria; Pfizer - Research Funding; Sobi - Research Funding; CSL Behring - Research Funding; Sobi - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); BioMarin - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); CSL Behring - Consultancy (Includes expert testimony); Johnson & johnson - Consultancy (Includes expert testimony)